Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
PIQLF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.04 Max: 2.41
Current: 0.06
During the past 11 years, the highest Debt-to-Equity Ratio of Proteomics International Laboratories was 2.41. The lowest was 0.01. And the median was 0.04.
PIQLF's Debt-to-Equity is ranked better than 68.43% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs PIQLF: 0.06
Proteomics International Laboratories (OTCPK:PIQLF) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Proteomics International Laboratories Debt-to-Equity Related Terms
Proteomics International Laboratories Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteomics International Laboratories Debt-to-Equity Chart
PIQLF vs VRTX, REGN, ALNY: Debt-to-Equity Comparison
For the Biotechnology subindustry, Proteomics International Laboratories's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Proteomics International Laboratories Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Proteomics International Laboratories's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Proteomics International Laboratories's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteomics International Laboratories (PIQLF) has a Debt-to-Equity of 0.06 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Proteomics International Laboratories and its competitors. This is 50% above median its historical median of 0.04. Over the past decade, Proteomics International Laboratories' Debt-to-Equity has ranged from 0.01 to 2.41. According to the industry distribution chart, Proteomics International Laboratories ranks #305 out of 966 companies in the Biotechnology industry, placing it in the top 31.6%.
Is Proteomics International Laboratories' Debt-to-Equity too high?
Proteomics International Laboratories' current Debt-to-Equity of 0.06 is 50% above median its 10-year median of 0.04. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 2.41. The Biotechnology industry median Debt-to-Equity is 0.16. Proteomics International Laboratories' value of 0.06 is 62.5% below this industry median. Based on the distribution chart, Proteomics International Laboratories ranks #305 out of 966 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Proteomics International Laboratories has a GF Scoreâ„¢ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Proteomics International Laboratories' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Proteomics International Laboratories ranks #305 out of 966 companies for Debt-to-Equity. This puts Proteomics International Laboratories in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Proteomics International Laboratories' value of 0.06 is 62.5% below this benchmark. Historically, Proteomics International Laboratories' own Debt-to-Equity has ranged from 0.01 to 2.41 over the past decade. While the company's 10-year median is 0.04 vs. the industry median of 0.16, Proteomics International Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Proteomics International Laboratories's current Debt-to-Equity of 0.06 is 62.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Proteomics International Laboratories and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Proteomics International Laboratories's current Debt-to-Equity is 0.06, which is 50% above median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteomics International Laboratories stock overvalued right now?
Proteomics International Laboratories (PIQLF) has a current Debt-to-Equity of 0.06. The stock's GF Value™ is $0.64, compared to a current price of $0.26 — trading 59.4% below its estimated fair value. The current Debt-to-Equity is 0.06, which is 50% above median its 10-year median of 0.04 and 62.5% below the Biotechnology industry median of 0.16. Proteomics International Laboratories' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Proteomics International Laboratories (PIQLF), the current Debt-to-Equity is 0.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Proteomics International Laboratories (PIQLF) Overvalued in 2026?
Based on GuruFocus' analysis, Proteomics International Laboratories stock appears to be undervalued.
The current stock price of $0.26 is trading 59.4% below its estimated GF Value™ of $0.64.
Key valuation signals for PIQLF:
Debt-to-Equity: 0.06 (50% above median its 10-year median of 0.04)
GF Value™: $0.64 vs. price of $0.26 (59.4% below fair value)
Industry Position: 62.5% below the Biotechnology median (#305 of 966)
No single metric tells the full story. See the PIQLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Proteomics International Laboratories Business Description
Proteomics International Laboratories Ltd is a biological research and drug discovery company. It is a pioneering medical technology company operating at the forefront of predictive diagnostics and precision medicine. The Company specialises in proteomics-the industrial-scale study of the structure and function of proteins. Its pipeline includes Promarker, Pipeline PromarkerD, PromarkerEndo, PromarkerEso, and OxiDx.
31GF Score
Get the complete analysis for PIQLF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PIQLF has been successfully added to your 
